Filtered By:
Vaccination: Varicella-Zoster Virus Vaccine
Countries: USA Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 161 results found since Jan 2013.
Lower risk for COVID-19 hospitalization among patients in the United States with past vaccinations for herpes zoster and tetanus, diphtheria and pertussis
Prev Med Rep. 2023 Jun 25;35:102302. doi: 10.1016/j.pmedr.2023.102302. eCollection 2023 Oct.ABSTRACTInfluenza, tetanus, diphtheria, and herpes zoster (HZ) vaccination received within 10 years of the COVID-19 pandemic have been associated with less severe COVID-19 infection. We expanded on this evidence to determine if a receiving two different vaccinations (i.e., HZ and tetanus, diphtheria, and pertussis (Tdap)) was associated with a lower risk for COVID-19 hospitalization. De-identified medical record data from a large mid-western health care system was used to determine if, compared to those with neither HZ or Tdap vacci...
Source: Herpes - July 13, 2023 Category: Infectious Diseases Authors: Joanne Salas John E Morley Daniel F Hoft Jeffrey F Scherrer Source Type: research
Proceedings of the expert consensus group meeting on herpes zoster disease burden and prevention in India: An opinion paper
Hum Vaccin Immunother. 2023 Jun 9:2220608. doi: 10.1080/21645515.2023.2220608. Online ahead of print.ABSTRACTHerpes zoster (HZ) is a debilitating viral infection causing a dermatomal vesicular rash. Many known risk factors exist in India and adults >50 years of age may be especially susceptible to HZ. However, HZ is not a notifiable disease in India and data on incidence and disease burden is lacking. An Expert Consensus Group meeting was conducted with experts from relevant specialties to discuss HZ disease, its local epidemiology, and suggestions for implementing HZ vaccination in the Indian healthcare system. Current...
Source: Herpes - June 9, 2023 Category: Infectious Diseases Authors: V Ramasubramanian Agam Vora Youness Lagoubi Nicolas Lecrenier Yashpal Chugh Source Type: research
Top 100 Most-Cited Papers in Herpes Zoster from 2000 to 2022: A Bibliometric Study
CONCLUSION: In terms of the quantity of T100 articles, researchers, and organizations, the US is the predominant country. The most T100 papers were published in the special journal Clinical Infectious Diseases. The most academic focus remain the remedies for postherpetic neuralgia and vaccine development for individualized groups.PMID:37273270 | PMC:PMC10237222 | DOI:10.2147/JPR.S409616
Source: Herpes - June 5, 2023 Category: Infectious Diseases Authors: Ning Gao Meng Li Weiming Wang Lei Wang Zhen Liu Yufeng Guo Source Type: research
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
CONCLUSIONS: These findings highlight the high economic burden of HZ among individuals with RA in the United States. Strategies to reduce the risk of HZ in patients with RA (such as vaccination) may serve to reduce this burden. Video abstract.PMID:37219822 | DOI:10.1007/s40744-023-00549-x
Source: Herpes - May 23, 2023 Category: Infectious Diseases Authors: David Singer Philippe Thompson-Leduc Sara Poston Deepshekhar Gupta Wendy Y Cheng Siyu Ma Francesca Devine Alexandra Enrique Mei Sheng Duh Jeffrey R Curtis Source Type: research
Clinical and Economic Implications of Increasing Access to Herpes Zoster Vaccination Rate in Community Pharmacies
CONCLUSIONS: Community pharmacy-based herpes zoster vaccination was less costly and gained more QALYs and was associated with improved other clinical outcomes in the State of Utah. This study might be used as a model for future evaluations of other community pharmacy-based vaccination programs in the United States.PMID:37207710 | DOI:10.1016/j.japh.2023.05.012
Source: Herpes - May 19, 2023 Category: Infectious Diseases Authors: Alexandre H Watanabe Sajesh K Veettil Lan My Le Elizabeth Bald Casey Tak Nathorn Chaiyakunapruk Source Type: research
Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data
This study quantifies RZV coverage and assesses predictors for RZV vaccination using a U.S. claims database. Univariate linear regression provided annual prevalence of RZV vaccination and multivariable logistic regression provided ORs and 95% CIs for associations between predictors and RZV vaccination. A total of 4,124,315 individuals (19,080,914 person-years) were included in this study. Since receiving FDA approval for the prevention of HZ, RZV coverage (of at least one dose) has reached approximately 17% within the eligible U.S. population by January 2021, although significant disparities between demographic groups were...
Source: Vaccine - May 7, 2023 Category: Allergy & Immunology Authors: Chad Y Lewis Kunal Mishra Yuwei Sun Samantha J Sechrist Benjamin F Arnold Nisha R Acharya Source Type: research
Vaccine co-administration in adults: An effective way to improve vaccination coverage
Hum Vaccin Immunother. 2023 Apr 11:2195786. doi: 10.1080/21645515.2023.2195786. Online ahead of print.ABSTRACTThe ongoing COVID-19 pandemic highlights that complications and mortality associated with infectious diseases increase with age. Various vaccines are recommended for adults, but coverage rates remain suboptimal. Although co-administration would improve vaccine uptake and timely immunization, this is not routine practice in adults. We review key data on co-administration of vaccines in children and adults to reassure healthcare providers about its safety and advantages. In European countries and the United States, c...
Source: Herpes - April 11, 2023 Category: Infectious Diseases Authors: Paolo Bonanni Robert Steffen J örg Schelling Lina Balaisyte-Jazone Inga Posiuniene Maciej Zato ński Pierre Van Damme Source Type: research
Epidemiology of Clostridioides difficile Infections in Germany, 2010-2019: A Review from Four Public Databases
CONCLUSIONS: All four public sources documented a decline in CDI cases since 2013, but the disease burden remains substantial and warrants continued attention as a severe public health challenge.PMID:36897556 | DOI:10.1007/s40121-023-00785-2
Source: Herpes - March 10, 2023 Category: Infectious Diseases Authors: Gordon Brestrich Frederick J Angulo Fabian K Berger Christian Br ösamle Stefan Hagel Andreas Leischker Christoph L übbert Friederike Maechler Sophie-Susann Merbecks Nadia Minarovic Jennifer C Mo ïsi Lutz von M üller Phillip A Reuken Thomas Weinke Holl Source Type: research
Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
This study evaluates the public health impact of recombinant zoster vaccine (RZV) relative to no HZ vaccination for the prevention of HZ among adults aged ≥18 years diagnosed with selected cancers in the United States (US). A static Markov model was used to simulate three cohorts of individuals who are IC with cancer (time horizon of 30 years; one-year cycle length): hematopoietic stem cell transplant (HSCT) recipients, patients with breast cancer (BC; a solid tumor example), and patients with Hodgkin's lymphoma (HL; a hematological malignancy example). Cohort sizes reflect the estimated annual incidence of each conditio...
Source: Herpes - March 7, 2023 Category: Infectious Diseases Authors: Desmond Curran Brandon J Patterson Justin Carrico Ahmed Salem Elizabeth M La St éphane Lorenc Katherine A Hicks Sara Poston Christopher F Carpenter Source Type: research
